Intermediate-dose Versus Low-dose Low–molecular-weight Heparin in Pregnant and Postpartum Women With a History of Venous Thromboembolism (Highleow study): An Open-label, Multicenter, Randomized, Controlled Trial

( Lancet . 2022;400:1777–1787) Venous thromboembolism (VTE) and subsequent major bleeding are leading causes of maternal morbidity and mortality worldwide, and the risk for recurrence increases for women with a history of VTE. Despite this, evidence-based research on thromboprophylaxis strategies is lacking and the optimal dose of low–molecular-weight heparin (LMWH) thromboprophylaxis during the peripartum and postpartum periods is uncertain. This study aimed to assess the safety and efficacy of low-dose compared to intermediate-dose LMWH for pregnant women with past occurrences of VTE.